Clinical Trial Update: Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing intravenous iclaprim to vancomycin for hospital-acquired, ventilator-associated, or healthcare-associated pneumonia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthcare-associated Pneumonia
• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Iclaprim (iclaprim)
• Vancomycin (vancomycin)

Snippet

Sponsor: Arpida AG | Conditions: Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia | Phase 2 | Status: TERMINATED